MDGL PDUFA decision: a negative outcome, -10.8%

On March 14, 2024, Madrigal Pharmaceuticals, Inc. reached its PDUFA decision. The result was a negative outcome, and the stock moved -10.8% in the window around the event. It had already run +27.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.